The first experience with brolucizumab for neovascular age-related macular degeneration
<p> <b>A.N. Kulikov, D.S. Maltsev, A.Yu. Malafeeva, S.M. Perminova, V.R. Zhalimova, <br> A.S. Vasiliev, A.A. Kazak</b> </p> <p> <b>S.M. Kirov Military Medical Academy, St. Petersburg, Russian Federation</b> </p> <p> <i><b>A...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Prime-Media
2022-05-01
|
| Series: | РМЖ "Клиническая офтальмология" |
| Online Access: | http://clinopht.com/upload/iblock/796/7962935cfc5d0f0f1c1388eae1b8c5fe.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>
<b>A.N. Kulikov, D.S. Maltsev, A.Yu. Malafeeva, S.M. Perminova, V.R. Zhalimova, <br>
A.S. Vasiliev, A.A. Kazak</b>
</p>
<p>
<b>S.M. Kirov Military Medical Academy, St. Petersburg, Russian Federation</b>
</p>
<p>
<i><b>Aim</b>: to assess the efficacy and safety of brolucizumab in Russian patients with neovascular age-related macular degeneration (nAMD).</i>
</p>
<p>
<i><b>Patients and Methods:</b> this study enrolled 47 patients with nAMD divided into two groups. Group 1 included 13 treatment-na</i><i>ï</i><i>ve patients/13 eyes </i><i>(12 men and 1 woman, mean age 72.4±9.5 years, mean best-corrected visual acuity (BCVA) 0.43±0.32). Group 2 included 34 patients having active nAMD despite ongoing treatment/34 eyes (25 men and 9 women, mean age 74.1±8.0 years, mean BCVA 0.46±0.25). All patients received at least two intravitreal injections of brolucizumab (in total, 137 injections) with a 1-month interval. Patients were examined one month after the 2<sup>nd</sup> injections. BCVA, central macular thickness (CMT), macular volume (MV), sub/intraretinal fluid, and adverse events were evaluated.</i>
</p>
<p>
<i><b>Results</b>: in group 1, a significant increase in BCVA from 34.9±6.6 letters to 44.1±4.2 letters (p=0.02) was reported. Meanwhile, in group 2, BCVA remained unchanged (35.0±3.5 letters before treatment vs. 33.8±3.7 letters after treatment, p>0.05). In group 1, CMT and MV significantly reduced, while in group 2, only MV significantly reduced (p<0.05). A significant reduction in the cumulative rate of sub/intraretinal fluid was detected in both groups (p<0.05).</i>
</p>
<p>
<i><b>Conclusions</b>: treatment-na</i><i>ï</i><i>ve patients who received brolucizumab demonstrated a significant improvement of anatomical and functional parameters. Meanwhile, patients with active nAMD despite ongoing treatment who received brolucizumab demonstrated a significant reduction in disease activity and tendency to the improvement of anatomical (but not functional) parameters.</i>
</p>
<p>
<i><b>Keywords</b>: age-related macular degeneration, brolucizumab, optical coherence tomography, anti-VEGF therapy.</i>
</p>
<p>
<i><b>For citation:</b> Kulikov A.N., Maltsev D.S., Malafeeva A.Yu. et al. The first experience with brolucizumab for neovascular age-related macular degeneration. Russian Journal of Clinical Ophthalmology. 2022;22(2):108–</i><i>115</i><i> (in Russ.). DOI: 10.32364/2311-7729-2022-22-2-108-</i><i>115</i><i>.</i>
</p>
<i><br>
</i><br> |
|---|---|
| ISSN: | 2311-7729 2619-1571 |